Novo will drop its U.S. list price for its Fiasp by 75% and for Tresiba by 72%, the Danish company said in a release. The new ...

Compared with the administration of regular insulin at least 30 minutes before meals, the administration of rapid-acting insulin analogs 15 to 20 minutes before meals leads to maximal reduction of ...

The global rapid acting insulin market was valued at $7,100 million in 2019, and is projected to reach $8,925 million by 2027 at a CAGR of 4.1% from 2020 to 2027. The growth of the global rapid acting ...

Sanofi’s Admelog (insulin lispro) is approved in type 1 and type 2 diabetes as a follow-on drug to Humalog, a rapid-acting insulin that is Lilly’s top selling drug, bringing in almost $700 ...

Additionally, the rapid-acting insulin analogs segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for effective postprandial glucose control ...

For instance, Sanofi stated in January 2024 that a phase 3 clinical trial for individuals with type 2 diabetes will be starting in January 2024 for their investigational insulin biosimilar, SAR342434.

Clin Drug Invest. 2004;24(12):695-717.

Build financial models with decades of earnings stats, ratios, and valuation data — all exportable — to power your trade ideas.